de Beauchamp, L., Himonas, E. and Helgason, G. V. (2022) Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. Leukemia, 36(1), pp. 1-12. (doi: 10.1038/s41375-021-01416-w) (PMID:34561557) (PMCID:PMC8727299)
![[img]](https://eprints.gla.ac.uk/style/images/fileicons/text.png) |
Text
252467.pdf - Published Version Available under License Creative Commons Attribution. 1MB |
Abstract
While the understanding of the genomic aberrations that underpin chronic and acute myeloid leukaemia (CML and AML) has allowed the development of therapies for these diseases, limitations remain. These become apparent when looking at the frequency of treatment resistance leading to disease relapse in leukaemia patients. Key questions regarding the fundamental biology of the leukaemic cells, such as their metabolic dependencies, are still unresolved. Even though a majority of leukaemic cells are killed during initial treatment, persistent leukaemic stem cells (LSCs) and therapy-resistant cells are still not eradicated with current treatments, due to various mechanisms that may contribute to therapy resistance, including cellular metabolic adaptations. In fact, recent studies have shown that LSCs and treatment-resistant cells are dependent on mitochondrial metabolism, hence rendering them sensitive to inhibition of mitochondrial oxidative phosphorylation (OXPHOS). As a result, rewired energy metabolism in leukaemic cells is now considered an attractive therapeutic target and the significance of this process is increasingly being recognised in various haematological malignancies. Therefore, identifying and targeting aberrant metabolism in drug-resistant leukaemic cells is an imperative and a relevant strategy for the development of new therapeutic options in leukaemia. In this review, we present a detailed overview of the most recent studies that present experimental evidence on how leukaemic cells can metabolically rewire, more specifically the importance of OXPHOS in LSCs and treatment-resistant cells, and the current drugs available to target this process. We highlight that uncovering specific energy metabolism dependencies will guide the identification of new and more targeted therapeutic strategies for myeloid leukaemia.
| Item Type: | Articles |
|---|---|
| Additional Information: | The work was supported by University of Glasgow MVLS DTP Studentship, MRC confidence in Concept 2018 (MC_PC_18048), The Howat Foundation and Cancer Research UK (C57352/A29754). |
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Helgason, Professor Vignir |
| Authors: | de Beauchamp, L., Himonas, E., and Helgason, G. V. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
| Journal Name: | Leukemia |
| Publisher: | Springer Nature |
| ISSN: | 0887-6924 |
| ISSN (Online): | 1476-5551 |
| Published Online: | 24 September 2021 |
| Copyright Holders: | Copyright © 2021 The Authors |
| First Published: | First published in Leukemia 36(1): 1-12 |
| Publisher Policy: | Reproduced under a Creative Commons licence |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information